SWOG'S overall mission is to design, direct, and participate in research that leads to more effective prevention, detection, treatment, and surveillance of cancers in adolescents, young adults, and adults. Our overarching goal is to improve survival, quality of life, and the survivorship experience for those with cancer. The SWOG NCORP Research Base is an integral part of the Group's research effort. The Research Base has the established organizational structure to conduct multi-center prevention, control, and screening/surveillance trials;additionally, we have the successful track record, expertise, and leadership to stimulate and lead cancer care delivery research. We strongly believe, in line with the mission of NCORP, that engaging community oncologists in collaborative research will facilitate the uptake of effective, evidence-based practices.

Public Health Relevance

SWOG will collaboratively design, conduct, and accrue to cancer prevention, control, and screening/surveillance trials, and will study and enhance cancer care delivery, in order to significantly improve the lives of patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
1UG1CA189974-01
Application #
8790607
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Xie, Heng
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$6,414,996
Indirect Cost
$691,441
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Lee, Shing M; Hershman, Dawn L; Miao, Jieling et al. (2018) Estimating global treatment toxicity burden from adverse-event data. Cancer 124:858-864
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Unger, Joseph M; Hershman, Dawn L; Till, Cathee et al. (2018) Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 110:1208-1215
Sucheston-Campbell, Lara E; Clay-Gilmour, Alyssa I; Barlow, William E et al. (2018) Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Pharmacogenet Genomics 28:49-55
Carlson, Josh J; Kim, David D; Guzauskas, Gregory F et al. (2018) Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study. Cancer Med 7:4251-4260
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095
Klein, Alison P; Wolpin, Brian M; Risch, Harvey A et al. (2018) Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun 9:556
Greenlee, Heather; Lew, Danika L; Hershman, Dawn L et al. (2018) Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008). Obesity (Silver Spring) 26:1539-1549

Showing the most recent 10 out of 143 publications